Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

Cerebral Cavernous Malformation Clinical Trial

— AT CASH EPOC  

Official title:

Phase I-II Randomized, Placebo-Controlled, Single-Blinded, Single-Site Clinical Trial of Atorvastatin in the Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02603328
• Other study ID #: IRB18-0445
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: July 17, 2018
• Est. completion date: June 30, 2025

Study information

• Verified date: October 2023
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by validated quantitative susceptibility mapping (QSM) MRI studies in patients who suffered a symptomatic bleed within the preceding one year.

Description:

This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by validated quantitative susceptibility mapping (QSM) MRI studies in patients who suffered a symptomatic bleed within the preceding one year. Subjects will also be assessed by lesional and brain vascular permeability MRI using dynamic contrast enhanced quantitative perfusion (DCEQP) and a number of clinical evaluation tools. Subjects shall be followed for 2 years from randomization, the period of highest likelihood of rebleed after a recent CCM hemorrhage. Subjects will undergo clinical and MRI evaluations at baseline, and at 12 and 24 months during the study period. Enrolled subjects and the treating team will be blinded to treatment group allocation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: June 30, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of CCM of any genotype supported by relevant imaging studies.

2. Symptomatic CCM bleeding event within 1 year prior to enrollment.

3. Must be willing/able to travel to the study site for all study visits (baseline, 12 months, and 24 months) over the course of the study period.

Exclusion Criteria:

1. Pre-menopausal women who are breastfeeding, pregnant or likely to get pregnant during the study period.

2. Previous cranial irradiation or surgical/radiosurgical treatment of CCM lesion.

3. Failure to pass MRI safety screening (claustrophobia, metal implant . . . etc)

4. Known allergy or intolerance to gadolinium.

5. Severely impaired renal function (eGFR < 60ml/min), active renal disease or status post-kidney transplants.

6. Statin therapy, for any indication, for more than 7 continuous days or greater than 14 total days within 12 months preceding enrollment.

7. Indication to use statin medication for current approved indication, unrelated to CCM

8. Known allergy or intolerance to statins

9. Liver dysfunction or active liver disease (including chronic viral hepatitis) defined as baseline serum transaminases levels twice the upper range of normal.

10. Previous diagnosis of skeletal muscle disorders of any cause (myopathy), or baseline creatine kinase level five times the upper range of normal.

11. Currently treated with or likely to need treatment with one or more of prohibited medications listed in the protocol.

12. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.

13. Serious illness (requiring systemic treatment and/or hospitalization) until subject either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 30 days prior to study entry.

14. Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated, including conditions resulting in or precipitating myopathy (e.g. HIV, uncontrolled hypothyroidism).

15. In the investigator's opinion, the patient is unstable, and would benefit from a specific intervention rather than treatment with atorvastatin.

16. Inability or unwillingness of subject or legal guardian/representative to give written informed consent.

17. No documentation of valid healthcare insurance.

18. No medical record confirmation of primary care physician.

Related Conditions & MeSH terms

• Cerebral Cavernous Malformation
• Congenital Abnormalities
• Hemorrhage

Intervention

Drug:
• Atorvastatin
40-80 mg OD

Other:
• Placebo
inactive

Locations

Country	Name	City	State
United States	University of Chicago	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
University of Chicago	Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	mean percent change in lesional QSM per year (called the change score)	Each patient contributes two outcome measurements (at year 1 and year 2) based on intention-to-treat. Evaluation of the intervention on this outcome will be performed as a time-averaged difference between two arms using a repeated measures analysis implemented as an unadjusted linear mixed model. Patients with outcome measurements in both periods will be included in the initial intention-to-treat analysis. In cases with multiple lesions, only QSM measurements in the lesion with initial hemorrhage (index lesion) shall be considered for the primary outcome assessment.	End of study (24-month) MRI scan
Primary	Percent QSM change per year	A secondary analysis of the percent QSM change per year shall be conducted per treatment rendered for all patients with at least one annual epoch of measurements.	End of study (24-month) MRI scan
Secondary	Changes in DCEQP vascular permeability measurements in the index lesion and in brain (white matter far from lesion)	Changes in DCEQP vascular permeability measurements in the index lesion and in brain (white matter far from lesion)	End of study (24-month) MRI scan
Secondary	Rates of QSM and DCEQP biomarker events	Rates of QSM and DCEQP biomarker events, representing increases in index lesional QSM or DCEQP above previously articulated "biomarker thresholds"; rates of clinically overt hemorrhages in the index lesion per adjudicated criteria; and rates of lesional expansion, defined as an increase in maximum lesion diameter on T2 sequences by 2 or more mm	End of study (24-month) MRI scan
Secondary	Adverse event rates		End of study (24-month) MRI scan
Secondary	Serious adverse event rates		End of study (24-month) MRI scan
Secondary	Drug compliance by tracking daily medication bottle opening	We plan to use a compliance device that would record every time the bottle was opened, thus allowing the study team to track compliance with the protocol and help keep subjects accountable.	End of study (24-month) MRI scan
Secondary	Changes in functional outcome as measured using the modified Rankin scale which measures the degree of disability or dependence in patients with neurological disability.	Using the modified Rankin scale, we will track subjects' functional outcome changes over the course of the trial.	End of study (24-month) MRI scan
Secondary	Impact of sex on primary and secondary outcomes (pre specified subgroup analyses)		End of study (24-month) MRI scan
Secondary	Impact of genotype on primary and secondary outcomes (pre specified subgroup analyses)		End of study (24-month) MRI scan
Secondary	Impact of lesion location on primary and secondary outcomes (pre specified subgroup analyses)		End of study (24-month) MRI scan